Lu AA47070

Lu AA47070 is a selective adenosine A_2A receptor antagonist that was under development for the treatment of Parkinson's disease but was never marketed.^[1][2][3] It has been found to reverse some of the effects of dopamine D₂ receptor antagonists like pimozide and haloperidol, for instance tremulous jaw movements, catalepsy, locomotor suppression, and other anti-motivational effects, in animals.^[2][4][5] The drug is a prodrug of Lu AA41063.^[6][7][3] It was discontinued in phase 1 clinical trials because it lacked the intended pharmacological properties in humans.^[7][1] Lu AA47070 was first described by 2008.^[8]

Lu AA47070

Clinical data
Other names	Lu-AA47070; LU AA 47070; LU-AA-47070
Drug class	Adenosine A2A receptor antagonist
Identifiers
IUPAC name [2-[4-(3,3-dimethylbutanoylamino)-3,5-difluorobenzoyl]imino-1,3-thiazol-3-yl]methyl dihydrogen phosphate
CAS Number	913842-25-8
PubChem CID	11947802
ChemSpider	62804024
UNII	S4AD6SAU9U
ChEMBL	ChEMBL1671940
Chemical and physical data
Formula	C17H20F2N3O6PS
Molar mass	463.39 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C)CC(=O)NC1=C(C=C(C=C1F)C(=O)N=C2N(C=CS2)COP(=O)(O)O)F
InChI InChI=1S/C17H20F2N3O6PS/c1-17(2,3)8-13(23)20-14-11(18)6-10(7-12(14)19)15(24)21-16-22(4-5-30-16)9-28-29(25,26)27/h4-7H,8-9H2,1-3H3,(H,20,23)(H2,25,26,27) Key:MSWIQSFUBYCFJE-UHFFFAOYSA-N